Taken as a whole, the available scientific and alternative evidence suggests that multiple sclerosis patients suffer from chronic inflammation caused by diets that contain inadequate antioxidants, omega-3 deficiencies, excess sugar, and foods that fail to significantly reduce oxidative stress. In addition, gluten, cow's milk, or some other allergen further promotes autoimmune disease. The coupe de grâe, however, is a thyroid hormone deficiency that causes an abnormal need for dopamine. Dopamine is very susceptible to oxidative stress and can break down to form toxins such as dopachrome and other chrome indoles. These, in turn, kill oligodendrocytes, the cells needed to repair the damage to myelin caused by chronic inflammation.Beyond this, a shortage of triiodothyronine inmultiple sclerosis patients appears to reduce their ability to produce new oligodendrocytes. Therefore, myelin deteriorates and the symptoms of multiple sclerosis worsen. Wilcoxon and Redei have shown that such associated thyroid malfunctions in adults may be triggered by environmental challenges early in life. This process is termed fetal programming.
This newly revised edition is completely reorganized, refocused, and updated throughout to provide a stronger focus on instilling hope in patients and helping them regain their independence. The special feature of this new edition is the incorporation of the Morgante Conceptual Framework of Hope, a model of care that helps nurses integrate the concept of hope into clinical practice. The book also illustrates how to deliver nursing care that is both culturally sensitive and life span appropriate.
A synthesis of current concepts about the evaluation, treatment, and future directions in MS. On the evaluation side, the authors review the use of MRI, magnetic resonance spectroscopy, functional MRI, and three-dimensional MRI, and consider the rapidly developing body of pathologic information they have yielded. On thetreatment side, the focus is on recently approved medications (Novantrone), new indications for medications ( CHAMPS Trial), medications in development (Oral Interferon Tau, Oral Copaxone, and Oral Cellcept), immunosuppressive therapy for both progressive disease and symptomatic therapy; the current medications for treating relapsing-remitting MS (Avonex, Betaseron, and Copaxone) are also discussed. For future directions, the authors present the current best thinking, as well as the latest discoveries in immunology relating to MS, including groundbreaking B-cell research and its applications to specific immunotherapies, and the use of immune markers for tracking the disease.